Boehringer’s Philosophy Of DealMaking: A Conversation With Ioannis Sapountzis And Scott DeWire
BY JOSEPH HAAS Executive Summary The German pharma’s top business development execs explain how they balance IO and targeted cancer therapy in their portfolio, views on major M&A and how to make deals during a global pandemic.
24 / September 2020
In an interview with Scrip, Boehringer Ingelheim International GmbH’s top business development executives offered their views on conducting transactions amid a pandemic, why a company usually focused on partnerships has bought three cancer biotechs in recent years, and how it generally views major M&A. Having been with the family-owned firm for about 15 years, Ioannis Sapountzis has graduated from leading US business development and licensing to overseeing BI’s global deal-making activity. (Also see “Boehringer Ingelheim’s Partnering Focus: An Interview With Ioannis Sapountzis” - Scrip, 30 Jun, 2017.) Stepping into his shoes earlier this year to head up US business development and licensing was Scott DeWire, a five-year veteran of BI.
© Informa UK Ltd 2020 (Unauthorized photocopying prohibited.)
